SPPI Spectrum Pharmaceuticals Inc.

+0.23  (+2%)
Previous Close 11.57
Open 11.59
Price To Book 4.4
Market Cap 1261578026
Shares 106,913,392
Volume 617,568
Short Ratio
Av. Daily Volume 1,431,575

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 top-line data due 2H 2019.
Non-small cell lung cancer (NSCLC) with exon 20 insertion mutation in EGFR or HER2
Phase 2 initiation announced March 30, 2017 with preliminary data released October 18, 2017 - ORR 73%.
Non-small cell lung cancer (NSCLC)
CRL received October 9, 2009. Approved April 29, 2011.
Colorectal cancer
CRL received July 5, 2009.
Non-Hodgkin’s lymphoma
CRL October 23 2015. Approved March 15 2016.
EVOMELA (melphalan) for Injection
Conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma
Phase 2 initiated March 2016. Ongoing.
Breast cancer
Failed to meet primary endpoint in Phase 3 trial - Apr 2012. PDUFA date December 11 2016. Advisory Committee Meeting September 14 2016 voted 14 - 0 against approval. CRL issued November 17, 2016. New Phase 3 trial initiation announced August 14, 2017.
QAPZOLA - Apaziquone
Bladder cancer
BLA filing announced December 27, 2018.
Chemotherapy-Induced Neutropenia
Approved July 7, 2014.
Peripheral T-Cell Lymphoma cancer
Phase 2 data at ASH December 2018.
Peripheral T-Cell Lymphoma cancer

Latest News

  1. Read This Before Buying Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Shares
  2. Spectrum Pharmaceuticals Announces Fourth Quarter and Full Year 2018 Financial Results Conference Call
  3. Spectrum Pharmaceuticals to Present Corporate Update at the Guggenheim Healthcare Talks Idea Forum on February 14
  4. Top 4 Small-Cap Stocks for 2018
  5. Spectrum Pharma Sells Marketed Portfolio in a Deal That Could Reach $300 Million
  6. Spectrum Pharma sells marketed portfolio for $160 million upfront, up to $140 million in milestone payments
  7. Spectrum Pharmaceuticals Sells Marketed Portfolio to Acrotech Biopharma L.L.C. to Focus on New and Innovative Therapies for Cancer Patients
  8. Spectrum Pharma Fully Enrolls 1St Cohort in Poziotinib Study
  9. Spectrum Pharmaceuticals Announces Full Enrollment of the Poziotinib EGFR Cohort for Previously Treated Non-Small Cell Lung Cancer Patients with Exon 20 Insertion Mutations
  10. Spectrum Pharma Files BLA for Neutropenia Candidate Rolontis
  11. Why J.C. Penney, Tesla, and Spectrum Pharmaceuticals Slumped Today
  12. Here's Why Spectrum Pharmaceuticals Fell as Much as 13.1% Today
  13. Spectrum Pharmaceuticals: Earnings Trends and Recent Developments
  14. Spectrum Pharmaceuticals: Financial Overview in December
  15. Spectrum Pharmaceuticals: Analysts’ Recommendations in December
  16. Spectrum Pharmaceuticals Announces Submission of Biologics License Application to the FDA for ROLONTIS® (eflapegrastim) as a Treatment for Chemotherapy-Induced Neutropenia
  17. Here's Why Spectrum Pharmaceuticals, Inc. Is Getting Beaten Down Today
  18. Spectrum Pharma Shares Plunge As FDA Refuses Breakthrough Designation For Lung Cancer Drug
  19. The Daily Biotech Pulse: Tilray Inks Cannabis Drink Pact, Double Delight For Merck, FDA Snub For Spectrum
  20. Today's Research Reports on Trending Tickers: Spectrum Pharmaceuticals and MannKind